Generic Name and Formulations:
Ocriplasmin 2.5mg/mL; per vial; soln for intravitreal inj after dilution; contains mannitol; preservative- and latex-free.
Indications for JETREA:
Treatment of symptomatic vitreomacular adhesion.
Give by intravitreal inj. 0.125mg (0.1mL of the diluted soln) once as a single dose to the affected eye.
For ophthalmic intravitreal inj only. Monitor for elevation in intraocular pressure immediately after inj. Monitor for decreased vision. Repeated administration in the same eye: not recommended. Treatment in the other eye is not recommended within 7 days of the initial inj. Pregnancy (Cat.C). Nursing mothers.
Vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, retinal edema; intraocular inflammation/infection/hemorrhage, increased intraocular pressure, yellowish vision.
Single-use vial (0.2mL)—1
Endocrinology Advisor Articles
- Behavioral Weight Loss Interventions May Prevent Obesity
- Executive Function Predicts T1D Management Into Emerging Adulthood
- Association Between Urine Complement Proteins and Kidney Disease, Mortality in T2D
- Intensive Blood Pressure Therapy Lowers Cardiovascular Risk in Diabetes
- Rates of Incident Type 2 Diabetes in Chronic Kidney Disease
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age
- LVAD in Heart Failure Linked to Improved Glycemic Control
- Fundamental Institutional Change Is Needed to Eliminate Sexual Harassment
- Gestational Diabetes Tied to Subsequent Glucose Disorders
- Association Health Plans Can Help Small Businesses Offer Coverage